Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
Sponsor: Affymax
A PHASE2 clinical study on Cancer and Chemotherapy Induced Anemia, this trial is completed. The trial is conducted by Affymax and has accumulated 7 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affymax
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Brno, Czechia
- • Gdansk, Poland
- • Hradec Králové, Czechia
- • Krakow, Poland
- • Lodz, Poland
- • London, United Kingdom
- • Olomouc, Czechia
- • Poznan, Poland
- • Příbram, Czechia
- • Szczecin, Poland